PF
RETA

Phoenix Financial’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Phoenix Financial’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-20,000
Closed -$1.84M – 442
2020
Q3 		$1.84M Buy
+20,000
New +$2.5M 0.08% 163

Other funds holding RETA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Phoenix Financial's RETA Position: Q4 2020 in Review

Phoenix Financial sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2020, closing a stake of 20,000 shares — an estimated $1.84M sold.

Phoenix Financial first reported a position in RETA in Q3 2020 and held it in 1 quarter. The position peaked at $1.84M in Q3 2020. 202 funds tracked by Wall St. Rank hold RETA as of Q4 2020.

  • Phoenix Financial reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2020 after selling out during the quarter.
  • Phoenix Financial sold 20,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2020, an estimated $1.84M.
  • Phoenix Financial first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2020 and held it in 1 quarter.
  • Phoenix Financial's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.84M in Q3 2020.
  • 202 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2020.

Based on Phoenix Financial's 13F filing for Q4 2020, filed 11 Feb 2021.